New insider activity at Bausch + Lomb Corporation ( (BLCO) ) has taken place on May 7, 2025.
Director Andrew Von-Eschenbach has made a notable investment in Bausch + Lomb Corporation by purchasing 1,695 shares of the company’s stock. This transaction is valued at $19,916, indicating a significant vote of confidence in the company’s future prospects.
Recent Updates on BLCO stock
Bausch + Lomb Corporation’s stock has seen several price target reductions following its Q1 2025 financial results. Analysts from H.C. Wainwright, Wells Fargo, BofA, and Citi have all lowered their price targets due to various factors. The company’s updated guidance did not account for potential tariff impacts, leading to uncertainties. The Q1 report revealed a revenue increase driven by Vision Care and Surgical segments, but also a GAAP net loss due to increased selling costs and a voluntary recall of enVista intraocular lenses. BofA noted a significant EBITDA miss due to the recall and a slowdown in the U.S. generics business, prompting a reduction in EBITDA guidance. Citi included a $20M EBITDA tariff impact in its model, despite it not being in the company’s guidance. These developments have led to a cautious outlook on the stock, with analysts adjusting their targets to reflect financial pressures and uncertainties.
Spark’s Take on BLCO Stock
According to Spark, TipRanks’ AI Analyst, BLCO is a Neutral.
Bausch + Lomb’s overall score reflects solid revenue growth and a strong gross margin, but significant challenges in profitability and cash flow. Technical analysis shows bearish trends, while valuation metrics indicate poor earnings performance. The earnings call provided some optimism with growth in key segments, though risks remain from Pharmaceuticals and tariff pressures.
To see Spark’s full report on BLCO stock, click here.
More about Bausch + Lomb Corporation
YTD Price Performance: -36.83%
Average Trading Volume: 819,858
Technical Sentiment Signal: Sell
Current Market Cap: $4.06B